June 2, 2010 -- Patients who have trouble controlling their blood sugar are 66% less likely to get diabetes if they take low doses of two diabetes drugs with different modes of action.
The finding comes from a four-year Canadian study of more than 200 patients with impaired glucose tolerance, a sign of impending type 2 diabetes. It's the first study to show that a low-dose drug cocktail -- Avandia plus metformin -- can prevent diabetes better than lifestyle intervention alone.
The low-dose combination appears to reduce the risk of common side effects for each drug, says study researcher Bernard Zinman, MD, director of the diabetes center at Toronto's Mount Sinai Hospital and professor of medicine at the University of Toronto.
"Remarkably, the effect of the combination was remarkably robust with over 60% decrease in risk of diabetes," Zinman tells WebMD. "And the well-known side effects did not appear. There was no weight gain, no fluid retention, fractures were equal in both the treatment and placebo groups, and while there was some diarrhea, it was low intensity."
The dosages used in the study were 2 milligrams of Avandia plus 500 milligrams of metformin. Avandia daily doses usually range from 4 milligrams to 8 milligrams and metformin daily doses usually range from 500 milligrams twice daily up to a maximum of 2,000 milligrams daily.
People who have trouble controlling their blood sugar are urged to lose weight, diet, and increase their exercise. This works very well. But not everyone is able to do this.
"People should always do lifestyle change first. The problem is, this is hard to achieve," Zinman says. "We did have a very structured lifestyle intervention as part of the treatment for both the treatment and placebo group in our study."
Zinman notes that the encouraging study findings must be verified in larger clinical trials. Spyros Mezitis, MD, PhD, an endocrinologist at New York's Lenox Hill Hospital, agrees.
"This is an important study, but we need large trials to explore all the issues related to combination therapy," Mezitis tells WebMD.
Avandia is one of two approved drugs (the other is Actos) in a class known as the thiazolidinediones. Both drugs increase the risk of heart failure. But Avandia has also been linked to increased risk of heart attack, although the drug's manufacturer, GlaxoSmithKline, disputes this risk.